What is it about?
Phase IIB dose ranging RCT to determine an appropriate dose to carry forward into Phase 3 studies
Featured Image
Why is it important?
First time to test a biased ligand of the AT1R in a larger cohort of AHF patients
Perspectives
Unfortunately, the study was neutral
Peter Pang
Indiana University System
Read the Original
This page is a summary of: Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF), European Heart Journal, April 2017, Oxford University Press (OUP),
DOI: 10.1093/eurheartj/ehx196.
You can read the full text:
Contributors
The following have contributed to this page
